Evidence map›Paper›PMID 42737593›Full record

ArticleInternational journal of molecular sciences2026

Phosphodiesterase 4 Inhibitor Roflumilast Ameliorates Polytrauma-Induced Acute Kidney Injury by Attenuating HMGB1 and Renal Inflammatory Pathways in Rats.

Caroline Gusson Shimoura, Dustin M Kneifel, Heaven D Sessions, Jeanette Rocha, Kassandra Gonzalez, Emily M Corbin, Venkata Yellepeddi, Brian J Kirkwood, Jose Salinas, Andrew D Meyer and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Caroline Gusson ShimouraExpeditionary Medical Systems Department, United States Army Institute of Surgical Research, 3698 Chambers Pass, Fort Sam Houston, TX 78234, USA.
Dustin M KneifelExpeditionary Medical Systems Department, United States Army Institute of Surgical Research, 3698 Chambers Pass, Fort Sam Houston, TX 78234, USA.
Heaven D SessionsExpeditionary Medical Systems Department, United States Army Institute of Surgical Research, 3698 Chambers Pass, Fort Sam Houston, TX 78234, USA.
Jeanette RochaExpeditionary Medical Systems Department, United States Army Institute of Surgical Research, 3698 Chambers Pass, Fort Sam Houston, TX 78234, USA.
Kassandra GonzalezExpeditionary Medical Systems Department, United States Army Institute of Surgical Research, 3698 Chambers Pass, Fort Sam Houston, TX 78234, USA.
Emily M CorbinResearch Support Directorate, United States Army Institute of Surgical Research, Fort Sam Houston, TX 78234, USA.ORCID 0009-0008-8208-387X
Venkata YellepeddiDivision of Clinical Pharmacology, Department of Pediatrics, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT 84132, USA.ORCID 0000-0003-3819-9054
Brian J KirkwoodExpeditionary Medical Systems Department, United States Army Institute of Surgical Research, 3698 Chambers Pass, Fort Sam Houston, TX 78234, USA.ORCID 0000-0001-7196-3101
Jose SalinasExpeditionary Medical Systems Department, United States Army Institute of Surgical Research, 3698 Chambers Pass, Fort Sam Houston, TX 78234, USA.
Andrew D MeyerExpeditionary Medical Systems Department, United States Army Institute of Surgical Research, 3698 Chambers Pass, Fort Sam Houston, TX 78234, USA.
Zhangsheng YangExpeditionary Medical Systems Department, United States Army Institute of Surgical Research, 3698 Chambers Pass, Fort Sam Houston, TX 78234, USA.

Funding

US Army Medical Research & Development Command CO240046, CO250068, and DM230026
6 · The paper itself

Abstract

Traumatic injury remains a critical global health challenge, with polytrauma frequently leading to multi-organ failure and mortality. A severe complication of polytrauma is acute kidney injury (AKI), which is driven by a massive systemic inflammatory response following the initial insult. This inflammation is exacerbated by the upregulation of phosphodiesterase 4 (PDE4) enzymes; therefore, PDE4 inhibition represents a rational therapeutic strategy. Roflumilast is an FDA-approved PDE4 inhibitor currently used for chronic obstructive pulmonary disease (COPD). This study evaluated the hypothesis that roflumilast can mitigate inflammation and prevent AKI in a polytrauma rat model. Anesthetized male Sprague-Dawley rats were randomly assigned to either a vehicle control group (

Indexed as

Acute Kidney InjuryAminopyridinesBenzamidesHMGB1 ProteinMultiple TraumaPhosphodiesterase 4 InhibitorsAnimalsCyclopropanesDisease Models, AnimalInflammationKidneyMaleRatsRats, Sprague-DawleyAminopyridinesBenzamidesCyclopropanesHbp1 protein, ratHMGB1 ProteinPhosphodiesterase 4 InhibitorsRoflumilastacute kidney injuryhemorrhageinflammationphosphodiesterase inhibitorroflumilasttrauma

Identifiers

PMID42737593
PMCPMC13565810

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.